首页> 外文OA文献 >TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

【2h】

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

机译：TAS-120克服了FGFR2融合症症患者患者的ATP竞争性FGFR抑制剂的抵抗力

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Lipika Goyal; Lei Shi; Leah Y. Liu; Ferran Fece de la Cruz; Jochen K. Lennerz; Srivatsan Raghavan; Ignaty Leschiner; Liudmila Elagina; Giulia Siravegna; Raymond W.S. Ng; Phuong Vu; Krushna C. Patra; Supriya K. Saha; Raul N. Uppot; Ron Arellano; Stephanie Reyes; Takeshi Sagara; Sachie Otsuki; Brandon Nadres; Heather A. Shahzade; Ipsita Dey-Guha; Isobel J. Fetter; Islam Baiev; Emily E. Van Seventer; Janet E. Murphy; Cristina R. Ferrone; Kenneth K. Tanabe; Vikram Deshpande; James J. Harding; Rona Yaeger; Robin K. Kelley; Alberto Bardelli; A. John Iafrate; William C. Hahn; Cyril H. Benes; David T. Ting; Hiroshi Hirai; Gad Getz; Dejan Juric; Andrew X. Zhu; Ryan B. Corcoran; Nabeel Bardeesy;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma [J] . Goyal Lipika, Shi Lei, Liu Leah Y., Cancer discovery. . 2019,第8期

机译：TAS-120克服了FGFR2融合局部肝内胆管癌患者患者的ATP-Compartive FGFR抑制剂的抵抗力
2. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma [J] . Goyal Lipika, Saha Supriya K., Liu Leah Y., Cancer discovery. . 2017,第3期

机译：多克隆次级FGFR2突变在FGFR2融合胆管癌患者中驱动了对FGFR抑制的抗性
3. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors [J] . Drilon Alexander, Nagasubramanian Ramamoorthy, Blake James F., Cancer discovery. . 2017,第9期

机译：下一代TRK激酶抑制剂克服了TRK融合阳性实体肿瘤患者对先前TRK激酶抑制的获得性抗性
4. Targeting fatty acid synthase to inhibit tumor growth and overcome taxane resistance [C] . Joshua J. Souchek, Lindsey Muraskin, Lucas Houser, Visualizing and Quantifying Drug Distribution in Tissue III . 2019

机译：靶向脂肪酸合酶以抑制肿瘤生长并克服紫杉烷抗性
5. Primary resistance to ATP-competitive mTOR inhibitors for the treatment of solid tumors. [D] . Ducker, Gregory Stuart. 2013

机译：治疗实体瘤对ATP竞争性mTOR抑制剂的主要耐药性。
6. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma [O] . Lipika Goyal, Supriya K. Saha, Leah Y. Liu, -1

机译：FGFR2融合阳性胆管癌患者多克隆继发FGFR2突变驱动获得性对FGFR抑制的抵抗
7. Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications [O] . M. Droz Dit Busset, S. Braun, B. El-Rayes, 2019

机译：具有表达FGFR2 - 融合或FGFR2突变/扩增的肝内胆管癌（ICCA）患者（DZB）在患者（PTS）中的疗效
8. Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway. [R] . Kraft, A. 2017

机译：通过调节pim激酶途径克服对akt蛋白激酶抑制剂的抗性。

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

著录项

引文网络

相似文献

相关主题

期刊订阅